Joshua K. Sabari, MD, discusses the efficacy outcomes from the Ideate-Lung02 trial, noting the 52.4% ORR, 5.9-month median DOR, and 12.2-month OS and emphasizing that a 12-month OS is clinically meaningful for this patient population following a median of 2 prior lines of therapy.
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat
Cancer Research UK (CRUK) has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its…
In this roundtable discussion, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, is joined by Tapan Kadia, MD, The University of Texas…
The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.
Genetic loss-of-function studies have facilitated the characterization of hematopoietic transcription factors (TFs) in both normal physiology and pathological conditions. The knockout or knockdown of a…
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
